Chiayin Chong

Dr. Chiayin Chong


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Journal of Paediatrics and Child Health
Verified
Journal Article
Closed access
PDF file
SSShoba N Selvanathan
Shoba N Selvanathan
SSSharline Suhumaran
Sharline Suhumaran
VSVinay K Sahu
Vinay K Sahu
CCChiayin Chong
Chiayin Chong
NTNatalie Woon Hui Tan
Natalie Woon Hui Tan
KTKoh Cheng Thoon
Koh Cheng Thoon

10 February 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
NMNyo Min
Nyo Min
YOYasmin Hui Binn Ong
Yasmin Hui Binn Ong
AHAlvin X. Han
Alvin X. Han
SHSi Xian Ho
Si Xian Ho
EYEmmerie Wong Phaik Yen
Emmerie Wong Phaik Yen
Justin Jang Hann CHUJustin Jang Hann CHU
Justin Jang Hann CHU
Background: While hand, foot and mouth disease (HFMD) is primarily self-resolving—soaring incidence rate of symptomatic HFMD effectuates economic burden in the Asia-Pacific region. Singapore has seen a conspicuous rise in the number of HFMD cases from 2010s. Here, we aims to identify the serology and genotypes responsible for such outbreaks in hospitals and childcare facilities. Methods: We studied symptomatic paediatric HFMD cases from 2013 to 2018 in Singapore. Surveillance for subclinical enterovirus infections was also performed in childcares at the same time period. Results: Genotyping 101 symptomatic HFMD samples revealed CV-A6 as the major etiological agent for recent outbreaks. We detected infections with CV-A6 (41.0%), EV-A71 (7%), CV-A16 (3.0%), coxsackievirus A2, CV-A2 (1.0%) and coxsackievirus A10, CV-A10 (1.0%). Phylogenetic analysis of local CV-A6 strains revealed a high level of heterogeneity compared against others worldwide, dissimilar to other HFMD causative enteroviruses for which the dominant strains and genotypes are highly region specific. We detected sub-clinical enterovirus infections in childcare centres; 17.1% (n = 245) tested positive for enterovirus in saliva, without HFMD indicative symptoms at the point of sample collection. Conclusions: CV-A6 remained as the dominant HFMD causative strain in Singapore. Silent subclinical enteroviral infections were detected and warrant further investigations.

14 September 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
CCChiayin Chong
Chiayin Chong
KKKai-Qian Kam
Kai-Qian Kam
JLJiahui Li
Jiahui Li
MMMatthias Maiwald
Matthias Maiwald
LLLiat Hui Loo
Liat Hui Loo
KTKoh Cheng Thoon
Koh Cheng Thoon
Chia Yin Chong, Kai-Qian Kam, Jiahui Li, Matthias Maiwald, Liat Hui Loo, Karen Donceras Nadua, Natalie Woon Hui Tan, Chee Fu Yung, Koh Cheng Thoon; Saliva is n

30 May 2019 in Journal of Paediatrics and Child Health
Verified
Journal Article
Closed access
PDF file
CCChiayin Chong
Chiayin Chong
RORina Y‐L Ong
Rina Y‐L Ong
VSValerie X‐F Seah
Valerie X‐F Seah
NTNatalie W‐H Tan
Natalie W‐H Tan
MCMei‐Yoke Chan
Mei‐Yoke Chan
KTKoh‐Cheng Thoon
Koh‐Cheng Thoon

1 August 2019 in Journal of Medical Microbiology
Verified
Journal Article
Open access
JCJ. C. Chan
J. C. Chan
CCChiayin Chong
Chiayin Chong
KTKoh Cheng Thoon
Koh Cheng Thoon
NTN. W. S. Tee
N. W. S. Tee
MMMatthias Maiwald
Matthias Maiwald
NTNatalie Woon Hui Tan
Natalie Woon Hui Tan
Objectives. Elizabethkingia meningoseptica is a multi-drug-resistant organism that is associated with high mortality and morbidity in newborn and immunocompromised patients. This study aimed to identify the best antimicrobial therapy for treating this infection. Methods. A retrospective descriptive study was conducted from 2010 to 2017 in a tertiary paediatric hospital in Singapore. Paediatric patients aged 0 to 18 years old with a positive culture for E. meningoseptica from any sterile site were identified from the hospital laboratory database. The data collected included clinical characteristics, antimicrobial susceptibility and treatment, and clinical outcomes. Results. Thirteen cases were identified in this study. Combination therapy with piperacillin/tazobactam and trimethoprim/sulfamethoxazole or a fluoroquinolone resulted in a cure rate of 81.8 %. The mortality rate was 15.4 % and neurological morbidity in patients with bacteraemia and meningitis remained high (75 %). Conclusions. Treatment with combination therapy of piperacillin/tazobactam and trimethoprim/sulfamethoxazole or a fluroquinolone was effective in this study, with low mortality rates being observed.

16 May 2023 in The Lancet Child & Adolescent Health
Verified
Journal Article
Open access
CYChee Fu Yung
Chee Fu Yung
DPDeanette Pang
Deanette Pang
KKKai-Qian Kam
Kai-Qian Kam
DLDavid C. Lye
David C. Lye
BOBenjamin Ong
Benjamin Ong
KTKelvin B Tan
Kelvin B Tan
Information on variant-specific vaccine protection and the effect of previous infection variant is scarce in children. We aimed to ascertain the level of protection conferred by BNT162b2 COVID-19 vaccination against omicron variant infection (BA.4 or BA.5, and XBB) in a previously infected national paediatric cohort. We also explored the association between sequence of previous infection (variant) and vaccination on protection. We did a retrospective, population-based cohort study using the national databases of all confirmed SARS-CoV-2 infections, vaccines administered, and demographic records maintained by the Ministry of Health, Singapore. The study cohort consisted of children aged 5–11 years and adolescents aged 12–17 years who had a previous SARS-CoV-2 infection from Jan 1, 2020, to Dec 15, 2022. People who were infected during the pre-delta period or were immunocompromised (received three vaccination doses [children 5–11 years old] and four vaccinations doses [adolescents 12–17 years old]) were excluded. Those who had multiple episodes of infection before the study start date, were not vaccinated before infection but completed three doses, received bivalent mRNA vaccine, or received non-mRNA vaccine doses were also excluded. All SARS-CoV-2 infections confirmed by reverse transcriptase polymerase chain reaction or rapid antigen testing were grouped into delta, BA.1, BA.2, BA.4 or BA.5, or XBB variants using a combination of whole-genome sequencing, S-gene target failure results, and imputation. For BA.4 or BA.5, the study outcome period was June 1–Sept 30, 2022, and for XBB variants the outcome period was Oct 18–Dec 15, 2022. Incidence rate ratios between vaccinated and unvaccinated were derived using adjusted Poisson regressions and vaccine effectiveness was estimated as (1–risk ratio) × 100%. 135 197 people aged 5–17 years (79 332 children and 55 865 adolescents) were included in the cohort for the vaccine effectiveness analysis against omicron BA.4 or BA.5, and 164 704 people aged 5–17 years (97 235 children and 67 469 adolescents) were included for the analysis against omicron XBB. Approximately 47% of participants were female and 53% were male. Among those previously infected, vaccine effectiveness against BA.4 or BA.5 infection in fully vaccinated children (two doses) was 74·0% (95% CI 67·7–79·1) and in adolescents (three doses) was 85·7% (80·2–89·6). Against XBB, protection conferred with full vaccination was lower at 62·8% (95% CI 42·3–76·0) in children and 47·9% (20·2–66·1) in adolescents. In children, receipt of two-dose vaccination before first SARS-CoV-2 infection provided them with the highest protection against subsequent BA.4 or BA.5 infection at 85·3% (95% CI 80·2–89·1); however, this was not shown to be the case for adolescents. First infection variant had an effect on vaccine effectiveness against omicron BA.4 or BA.5 reinfection in the following descending order: BA.2 conferred the highest protection (92·3% [95% CI 88·9–94·7] in children and 96·4% [93·5–98·0] in adolescents) followed by BA.1 (81·9% [75·9–86·4] in children and 95·0% [91·6–97·0] in adolescents), and delta which conferred the lowest protection (51·9% [5·3–75·6] in children and 77·5% [63·9–86·0] in adolescents). In previously infected children and adolescents, BNT162b2 vaccination provided additional protection against omicron BA.4 or BA.5 and XBB variants compared with those who remained unvaccinated. Hybrid immunity against XBB was lower than against BA.4 or BA.5, especially in adolescents. Early vaccination of previously uninfected children before their first SARS-CoV-2 exposure could potentially strengthen population immunity resilience against future variants. None.